Antiretroviral Therapy Current Drugs

被引：167

作者：

Pau, Alice K. ^{[1
]}

George, Jomy M. ^{[2
]}

机构：

[1] NIAID, Div Clin Res, NIH, Bethesda, MD 20892 USA

[2] Univ Sci Philadelphia, Philadelphia Coll Pharm, Dept Pharm Practice & Adm, Philadelphia, PA 19104 USA

来源：

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2014年 / 28卷 / 03期

关键词：

HIV; Antiretroviral therapy; Nucleoside/nucleotide reverse transcriptase inhibitors; Non-nucleoside reverse transcriptase inhibitors; Protease inhibitors; Integrase strand transfer inhibitors; Fusion inhibitor; CCR5; antagonist; HIV-INFECTED PATIENTS; RITONAVIR-BOOSTED ATAZANAVIR; MYOCARDIAL-INFARCTION; RALTEGRAVIR; EFAVIRENZ; HYPERSENSITIVITY; EFFICACY; ABACAVIR; AIDS; OSTEOMALACIA;

D O I：

10.1016/j.idc.2014.06.001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The rapid advances in drug discovery and the development of antiretroviral therapy is unprecedented in the history of modern medicine. The administration of chronic combination antiretroviral therapy targeting different stages of the human immunodeficiency virus' replicative life cycle allows for durable and maximal suppression of plasma viremia. This suppression has resulted in dramatic improvement of patient survival. This article reviews the history of antiretroviral drug development and discusses the clinical pharmacology, efficacy, and toxicities of the antiretroviral agents most commonly used in clinical practice to date.

引用

页码：371 / +

页数：33